Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01135563 · ClinicalTrials.gov registry record · Phase 1
Study of Vinblastine and Sirolimus in Children With Recurrent/Refractory Solid Tumours Including CNS Tumours
A Phase 1 study of Solid Tumors and Central Nervous System Tumors, sponsored by The Hospital for Sick Children.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 5
- Study locations
NCT01135563: Completed Phase 1 study of Solid Tumors and Central Nervous System Tumors, sponsored by The Hospital for Sick Children.
NCT01135563 is a Phase 1 study of Solid Tumors and Central Nervous System Tumors that has completed, run by The Hospital for Sick Children. The registered enrollment target is 14 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (95% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01135563, a Phase 1 study of Solid Tumors and Central Nervous System Tumors, has completed, sponsored by The Hospital for Sick Children.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is a Phase I study using vinblastine and sirolimus in patients with relapsed solid tumors including selected brain tumors and lymphoma. The investigators hypothesis is that the combination administration of weekly vinblastine and sirolimus is safe.
Primary Outcome
Maximum tolerated dose (as defined by protocol) of vinblastine in combination with sirolimus
Conditions Studied
Interventions
- DRUG Vinblastine and Sirolimus
Study Locations (5)
California
- Rady Children's Hospital-San Diego - San Diego
Missouri
- SSM Cardinal Glennon Children's Medical Center - St Louis
Vermont
- Fletcher Allen Health Care - Burlington
Ontario
- The Hospital for Sick Children - Toronto
Quebec
- CHU Sainte-Justine - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
What the finished NCT01135563 record still lists
NCT01135563 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which Vinblastine and Sirolimus is the first listed.
NCT01135563 lists 5 locations in 5 states (California, Missouri, Vermont).
Frequently Asked Questions
What is clinical trial NCT01135563 about?
NCT01135563 is a clinical study titled "Study of Vinblastine and Sirolimus in Children With Recurrent/Refractory Solid Tumours Including CNS Tumours". This study is a Phase I study using vinblastine and sirolimus in patients with relapsed solid tumors including selected brain tumors and lymphoma. The investigators hypothesis is that the combination administration of weekly vinblastine and sirolimus is safe.
What is the current status of trial NCT01135563?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2010-04. Estimated completion is 2012-04.
What conditions does trial NCT01135563 study?
This clinical trial studies the following conditions: Solid Tumors, Central Nervous System Tumors.
What interventions are being tested in trial NCT01135563?
The interventions under investigation include: Vinblastine and Sirolimus (DRUG).
Who is sponsoring clinical trial NCT01135563?
This trial is sponsored by The Hospital for Sick Children, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01135563 being conducted?
This trial has 5 study locations across California, Missouri, Vermont, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01135563's enrollment target sits among peer trials
14 120th of 125 higher than 5 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia